Mumbai : The Indian Pharmaceutical Market (IPM) has registered a growth of 1.1% for the month of February 2021, after registering a growth of 4.5% for the month of January 2021.
According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,46,104 crore for moving annual total (MAT) basis during February 2021. Amongst the top 10 corporates, Cipla exhibited the highest growth of 7.3 per cent, followed by Torrent Pharma at 5.5 per cent.
Amongst the 11 to 25 ranked corporates, Glenmark exhibited highest growth of 14.4 per cent followed by Himalaya at 13.3 per cent. Amongst the 26 to 50 ranked corporates, Apex registered the highest growth 20.4 per cent followed by JB Chemicals at 13.7 per cent.
Amongst the 51 to 75 ranked corporates, Danone registered the highest growth 33.7 per cent and Merck at 19.9 per cent. Amongst the 76 to 100 ranked corporates, Reckitt Benckiser exhibited the highest growth at 20.9 per cent, followed by Charak at 13.6 per cent.
While majority of the therapy areas have moved to the recovery path, a few therapy areas that contribute a significant chunk to the IPM are yet to show a positive traction.
Cardiac registered a monthly growth of 7.3% in February 2021 as compared to 8.8% in January 2021, while anti-diabetic registered growth of 4.3% in February 2021 as compared to 5.3% in January 2021. Respiratory medicines growth slumps to -20.3% in February 2021 as compared to -14.1% in January 2021.
Post unlockdown since June 2020 the struggle for anti-infectives at -2.7% in January 2021 continues -11.3% in February 2021 and its associated therapy like gastro exhibits growth of 9.9% in February 2021 as against 14.3% in January 2021.
Vitamins have shown a growth of 8.6% in February 2021 as compared to 12.2% in January 2021 and pain and analgesics are at 2.3% in February 2021 as against 5.0% in January 2021.